EMA Starts Review of Dexamethasone as COVID-19 Treatment

News
Article

EMA has started a review of dexamethasone as a treatment for adults with COVID-19 who require respiratory support and have been admitted to hospital.

The European Medicines Agency (EMA) has announced in a July 24, 2020 press release that it has started a review of dexamethasone as a treatment for adults with COVID-19 who require respiratory support and have been admitted to hospital.

Specifically, the regulatory agency is reviewing data from the RECOVERY study arm that looked at the effects of adding dexamethasone to usual care in adults receiving invasive ventilation, in those receiving oxygen (e.g., through a mask), or in those receiving no oxygen. In the study, any deaths that happened 28 days after starting dexamethasone treatment were recorded and preliminary results indicate that dexamethasone reduced mortality in patients receiving respiratory support compared with usual care.

With this review, EMA hopes to provide an opinion on the RECOVERY study and also on the potential use of dexamethasone for the treatment of adults with COVID-19. More information will be presented by the agency when available.

Source: EMA

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes